Cleveland BioLabs (CBLI) Reaches New 12-Month Low at $1.75
Cleveland BioLabs, Inc. (NASDAQ:CBLI) reached a new 52-week low on Wednesday . The company traded as low as $1.75 and last traded at $1.65, with a volume of 4952 shares trading hands. The stock had previously closed at $1.80.
Cleveland BioLabs (NASDAQ:CBLI) last released its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.08) earnings per share for the quarter. Cleveland BioLabs had a negative net margin of 252.38% and a negative return on equity of 65.94%. The firm had revenue of $0.39 million for the quarter.
Cleveland BioLabs Company Profile (NASDAQ:CBLI)
Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.
Featured Article: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.